Arovella Therapeutics (ASX:ALA) has presented new data at the American Association for Cancer Research Annual Meeting, showing that its CAR19-iNKT cells (ALA-101) display significant anti-tumour effects and survival benefits in aggressive leukemia models.

Arovella Therapeutics says ALA-101 has the potential to be a novel off-the-shelf cell therapy for treating CD19-expressing leukemias and lymphomas.

The data supports the ongoing development of ALA-101 and the progression to human Phase 1 clinical trials in 2024.

The company's share price is up 20% this morning.